Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Semafore Pharmaceuticals, a clinical stage drug discovery and development company, has achieved proof of concept in its Control Resulting from Inhibiting Multiple Pathways or CRIMP kinase platform by designing a small molecule that was demonstrated to inhibit members of both the Phosphoinositide-3-kinase pathway and the Ras-mitogen activated protein kinase pathway.
Subscribe to our email newsletter
Specifically, SF2626 has demonstrated the ability to inhibit both Phosphoinositide-3-kinase (PI3K) and MEK, the key component of the RAS/RAF/MEK/ERK pathway. Both PI3K and MEK are frequently activated in human tumors and are thus considered high value targets in treating cancer. SF2626 is the first combination PI3K and MEK kinase inhibitor that, in preclinical studies, blocks both pathways simultaneously, said Semafore.
Semafore has also said that its dual PI3K-MEK kinase inhibitor, SF2626, is a promising lead for targeting cancer. The company is actively seeking a partner for the continued development of SF2626 and other pipeline inhibitors.